产品
编 号：F117250
分子式：C17H15N9
分子量：345.36
分子式：C17H15N9
分子量：345.36
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
2mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1313725-88-0
产品详情
生物活性：
Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable c-Met inhibitor with IC50 s of 5 nM and 3 nM for c-Met and p-Met, respectively. Savolitinib (AZD-6094) selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. Antineoplastic activity.
体内研究：
Savolitinib (Compound 28；1-10.0 mg/kg；口服给药；每天；持续 21 天；无胸腺裸鼠) 在 U87MG 皮下异种移植模型中表现出剂量依赖性抑制肿瘤生长。此外，处理组中没有一只小鼠在实验期间表现出体重减轻。Animal Model:U87MG xenograft model in athymic nude mice
Dosage:1 mg/kg, 2.5 mg/kg and 10.0 mg/kg
Administration:Oral administration; daily; for 21 days
Result:Demonstrated dose-dependent tumor growth inhibition in a U87MG subcutaneous xenograft model.
Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable c-Met inhibitor with IC50 s of 5 nM and 3 nM for c-Met and p-Met, respectively. Savolitinib (AZD-6094) selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. Antineoplastic activity.
体内研究：
Savolitinib (Compound 28；1-10.0 mg/kg；口服给药；每天；持续 21 天；无胸腺裸鼠) 在 U87MG 皮下异种移植模型中表现出剂量依赖性抑制肿瘤生长。此外，处理组中没有一只小鼠在实验期间表现出体重减轻。Animal Model:U87MG xenograft model in athymic nude mice
Dosage:1 mg/kg, 2.5 mg/kg and 10.0 mg/kg
Administration:Oral administration; daily; for 21 days
Result:Demonstrated dose-dependent tumor growth inhibition in a U87MG subcutaneous xenograft model.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备